## Carlotta Marianecci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3595157/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	pH-responsive oleic acid based nanocarriers: Melanoma treatment strategies. International Journal of Pharmaceutics, 2022, 613, 121391.	5.2	8
2	Nano-Based Drug Delivery Systems of Potent MmpL3 Inhibitors for Tuberculosis Treatment. Pharmaceutics, 2022, 14, 610.	4.5	5
3	Almond oil O/W nanoemulsions: Potential application for ocular delivery. Journal of Drug Delivery Science and Technology, 2022, 72, 103424.	3.0	3
4	Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office. Pharmaceutics, 2022, 14, 1438.	4.5	0
5	Nanoemulsions of Satureja montana Essential Oil: Antimicrobial and Antibiofilm Activity against Avian Escherichia coli Strains. Pharmaceutics, 2021, 13, 134.	4.5	14
6	Surfactants, Nanomedicines and Nanocarriers: A Critical Evaluation on Clinical Trials. Pharmaceutics, 2021, 13, 381.	4.5	7
7	Hyaluronic Acid Derivative Effect on Niosomal Coating and Interaction with Cellular Mimetic Membranes. Molecules, 2021, 26, 3434.	3.8	7
8	Resveratrol-Loaded Nanoemulsions: In Vitro Activity on Human T24 Bladder Cancer Cells. Nanomaterials, 2021, 11, 1569.	4.1	8
9	Rifampicin–Liposomes for Mycobacterium abscessus Infection Treatment: Intracellular Uptake and Antibacterial Activity Evaluation. Pharmaceutics, 2021, 13, 1070.	4.5	13
10	Clinical Trials and Machine Learning: Regulatory Approach Review. Reviews on Recent Clinical Trials, 2021, 16, 341-350.	0.8	3
11	Influence of drug/lipid interaction on the entrapment efficiency of isoniazid in liposomes for antitubercular therapy: a multi-faced investigation. Colloids and Surfaces B: Biointerfaces, 2021, 208, 112054.	5.0	19
12	Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office. Pharmaceuticals, 2021, 14, 1321.	3.8	2
13	Different instrumental approaches to understand the chitosan coated niosomes/mucin interaction. Journal of Drug Delivery Science and Technology, 2020, 55, 101339.	3.0	13
14	Satureja montana L. Essential Oils: Chemical Profiles/Phytochemical Screening, Antimicrobial Activity and O/W NanoEmulsion Formulations. Pharmaceutics, 2020, 12, 7.	4.5	43
15	Antimicrobial Essential Oil Formulation: Chitosan Coated Nanoemulsions for Nose to Brain Delivery. Pharmaceutics, 2020, 12, 678.	4.5	32
16	Current Trends in ATRA Delivery for Cancer Therapy. Pharmaceutics, 2020, 12, 707.	4.5	37
17	Pentamidine niosomes thwart S100B effects in human colon carcinoma biopsies favouring <i>wt</i> p53 rescue. Journal of Cellular and Molecular Medicine, 2020, 24, 3053-3063.	3.6	21
18	Hydrophilic Silver Nanoparticles Loaded into Niosomes: Physical–Chemical Characterization in View of Biological Applications. Nanomaterials, 2019, 9, 1177.	4.1	30

CARLOTTA MARIANECCI

#	Article	IF	CITATIONS
19	Long-Lasting, Antinociceptive Effects of pH-Sensitive Niosomes Loaded with Ibuprofen in Acute and Chronic Models of Pain. Pharmaceutics, 2019, 11, 62.	4.5	15
20	Smart Nanovesicles for Drug Targeting and Delivery. Pharmaceutics, 2019, 11, 147.	4.5	10
21	inPentasomes: An innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice. Journal of Controlled Release, 2019, 294, 17-26.	9.9	36
22	Decoration of Nanovesicles with pH (Low) Insertion Peptide (pHLIP) for Targeted Delivery. Nanoscale Research Letters, 2018, 13, 391.	5.7	16
23	Chitosan Glutamate-Coated Niosomes: A Proposal for Nose-to-Brain Delivery. Pharmaceutics, 2018, 10, 38.	4.5	70
24	pH-sensitive niosomes: Effects on cytotoxicity and on inflammation and pain in murine models. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 538-546.	5.2	35
25	Neem oil nanoemulsions: characterisation and antioxidant activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 1265-1273.	5.2	50
26	Drug delivery in overcoming the blood–brain barrier: role of nasal mucosal grafting. Drug Design, Development and Therapy, 2017, Volume11, 325-335.	4.3	35
27	Niosomal approach to brain delivery: Development, characterization and in vitro toxicological studies. International Journal of Pharmaceutics, 2016, 511, 969-982.	5.2	33
28	pH-sensitive pHLIP® coated niosomes. Molecular Membrane Biology, 2016, 33, 51-63.	2.0	19
29	Niosomes as Drug Nanovectors: Multiscale pH-Dependent Structural Response. Langmuir, 2016, 32, 1241-1249.	3.5	42
30	Some recent advances on liposomal and niosomal vesicular carriers. Journal of Drug Delivery Science and Technology, 2016, 32, 256-269.	3.0	23
31	Visualization and quantification of magnetic nanoparticles into vesicular systems by combined atomic and magnetic force microscopy. AIP Conference Proceedings, 2015, , .	0.4	12
32	Gel-embedded niosomes: Preparation, characterization and release studies of a new system for topical drug delivery. Colloids and Surfaces B: Biointerfaces, 2015, 125, 291-299.	5.0	52
33	Biomedical Applications of Nanodiamonds: An Overview. Journal of Nanoscience and Nanotechnology, 2015, 15, 972-988.	0.9	76
34	Bioconjugation of gold-polymer core–shell nanoparticles with bovine serum amine oxidase for biomedical applications. Colloids and Surfaces B: Biointerfaces, 2015, 134, 314-321.	5.0	49
35	Nose to Brain Delivery: New Trends in Amphiphile-Based "Soft―Nanocarriers. Current Pharmaceutical Design, 2015, 21, 5225-5232.	1.9	15
36	Magnetic force microscopy. Biomatter, 2014, 4, e29507.	2.6	61

CARLOTTA MARIANECCI

#	Article	IF	CITATIONS
37	Niosomes from 80s to present: The state of the art. Advances in Colloid and Interface Science, 2014, 205, 187-206.	14.7	371
38	Thickness measurement of soft thin films on periodically patterned magnetic substrates by phase difference magnetic force microscopy. Ultramicroscopy, 2014, 136, 96-106.	1.9	19
39	Ammonium glycyrrhizinate-loaded niosomes as a potential nanotherapeutic system for anti-inflammatory activity in murine models. International Journal of Nanomedicine, 2014, 9, 635.	6.7	32
40	Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine. Current Medicinal Chemistry, 2014, 21, 4132-4153.	2.4	11
41	Polysorbate 20 vesicles as oral delivery system: In vitro characterization. Colloids and Surfaces B: Biointerfaces, 2013, 104, 200-206.	5.0	42
42	Interaction of pH-sensitive non-phospholipid liposomes with cellular mimetic membranes. Biomedical Microdevices, 2013, 15, 299-309.	2.8	22
43	The role of cytoskeleton networks on lipid-mediated delivery of DNA. Therapeutic Delivery, 2013, 4, 191-202.	2.2	22
44	Polysorbate 20 Vesicles as Multi-drug Carriers: in Vitro Preliminary Evaluations. Letters in Drug Design and Discovery, 2013, 10, 212-218.	0.7	0
45	Niosomes Encapsulating Ibuprofen–Cyclodextrin Complexes: Preparation and Characterization. Current Drug Targets, 2013, 14, 1070-1078.	2.1	25
46	Polysorbate 20 Vesicles as Multi-drug Carriers: in Vitro Preliminary Evaluations. Letters in Drug Design and Discovery, 2013, 10, 212-218.	0.7	5
47	Niosomes. , 2013, , 65-90.		1
48	Deformable Surfactant Vesicles Loading Ammonium Glycyrrhizinate: Characterization and In Vitro Permeation Studies. Letters in Drug Design and Discovery, 2012, 9, 494-499.	0.7	15
49	Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: Human and murine models. Journal of Controlled Release, 2012, 164, 17-25.	9.9	107
50	Factors Determining the Superior Performance of Lipid/DNA/Protammine Nanoparticles over Lipoplexes. Journal of Medicinal Chemistry, 2011, 54, 4160-4171.	6.4	51
51	A New Vesicle-loaded Hydrogel System Suitable for Topical Applications: Preparation and Characterization. Journal of Pharmacy and Pharmaceutical Sciences, 2011, 14, 336.	2.1	54
52	Pulmonary Delivery: Innovative Approaches and Perspectives. Journal of Biomaterials and Nanobiotechnology, 2011, 02, 567-575.	0.5	25
53	Novel pH-sensitive non-ionic surfactant vesicles: comparison between Tween 21 and Tween 20. Colloids and Surfaces B: Biointerfaces, 2011, 82, 18-24.	5.0	100
54	Existence of hybrid structures in cationic liposome/DNA complexes revealed by their interaction with plasma proteins. Colloids and Surfaces B: Biointerfaces, 2011, 82, 141-146.	5.0	41

#	Article	IF	CITATIONS
55	Multicompartment vectors as novel drug delivery systems: selective activation of Tγδ lymphocytes after zoledronic acid delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 153-161.	3.3	28
56	Programmed packaging of multicomponent envelope-type nanoparticle system for gene delivery. Applied Physics Letters, 2010, 96, .	3.3	5
57	Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: Characterization and interaction with human lung fibroblasts. Journal of Controlled Release, 2010, 147, 127-135.	9.9	107
58	Novel Tween® 20 derivatives enable the formation of efficient pH-sensitive drug delivery vehicles for human hepatoblastoma. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3021-3025.	2.2	24
59	Effect of Cholesterol on the Formation and Hydration Behavior of Solid-Supported Niosomal Membranes. Langmuir, 2010, 26, 2268-2273.	3.5	42
60	Potential dopamine prodrug-loaded liposomes: preparation, characterization, andin vitrostability studies. Journal of Liposome Research, 2010, 20, 250-257.	3.3	18
61	Influence of the formulation components on the properties of the system SLN-dextran hydrogel for the modified release of drugs. Journal of Microencapsulation, 2009, 26, 355-364.	2.8	18
62	Structural Stability and Increase in Size Rationalize the Efficiency of Lipoplexes in Serum. Langmuir, 2009, 25, 3013-3021.	3.5	41
63	Span <sup>®</sup> and Tween <sup>®</sup> neutral and pH-sensitive vesicles: Characterization and <i>in vitro</i> skin permeation. Journal of Liposome Research, 2009, 19, 332-340.	3.3	32
64	Effect of hydration on the structure of solid-supported Niosomal membranes investigated by in situ energy dispersive X-ray diffraction. Chemical Physics Letters, 2008, 462, 307-312.	2.6	20
65	pH-sensitive non-phospholipid vesicle and macrophage-like cells: Binding, uptake and endocytotic pathway. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 2749-2756.	2.6	49
66	Hybrid Niosome Complexation in the Presence of Oppositely Charged Polyions. Journal of Physical Chemistry B, 2008, 112, 3720-3727.	2.6	40
67	Physicochemical and biological study of selected hydrophobic polyethylenimine-based polycationic liposomes and their complexes with DNA. Bioorganic and Medicinal Chemistry, 2007, 15, 1504-1515.	3.0	62
68	Polysaccharide hydrogels for modified release formulations. Journal of Controlled Release, 2007, 119, 5-24.	9.9	855
69	Charge Renormalization in Planar and Spherical Charged Lipidic Aqueous Interfaces. Journal of Physical Chemistry B, 2006, 110, 4808-4814.	2.6	15
70	Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation. Journal of Drug Targeting, 2006, 14, 652-661.	4.4	32
71	Solid lipid nanoparticles incorporated in dextran hydrogels: A new drug delivery system for oral formulations. International Journal of Pharmaceutics, 2006, 325, 140-146.	5.2	83
72	Novel O-palmitoylscleroglucan-coated liposomes as drug carriers: Development, characterization and interaction with leuprolide. International Journal of Pharmaceutics, 2006, 325, 155-162.	5.2	29

CARLOTTA MARIANECCI

#	Article	IF	CITATIONS
73	Designing novel pH-sensitive non-phospholipid vesicle: Characterization and cell interaction. European Journal of Pharmaceutical Sciences, 2006, 28, 385-393.	4.0	49
74	Equilibrium particle aggregates in attractive colloidal suspensions. Journal of Physics Condensed Matter, 2005, 17, S3423-S3432.	1.8	18
75	Non-phospholipid vesicles for pulmonary glucocorticoid delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 59, 57-62.	4.3	58
76	New vesicular ampicillin-loaded delivery systems for topical application: characterization, in vitro permeation experiments and antimicrobial activity. Journal of Controlled Release, 2004, 95, 67-74.	9.9	46
77	Evaluation of rat striatal l-dopa and DA concentration after intraperitoneal administration of l-dopa prodrugs in liposomal formulations. Journal of Controlled Release, 2004, 99, 293-300.	9.9	51